Like electroporation, LNPs are suitable for delivering CRISPR-Cas9 as an mRNA47,48 and RNPs.49 In preclinical studies, LNP-mediated delivery of Cas9 mRNA and chemically modified sgRNA targeting Ttr in mice resulted in high levels of gene editing (>70%) and >97% knockdown in serum protein levels to correct transthyretin amyloidosis disease indication.50 However, toxicity from nanoparticles is a concern that will be evaluated in clinical trials for therapeutic gene editing in patients with hereditary transthyretin amyloidosis. The gene discussed is TTR; the disease is amyloidosis.